Table 3.
Proportion of samples with 7vPCV or non-7vPCV serotypes in Aboriginal and non-Aboriginal children who received 0, 1–2, or 3 doses of 7vPCV
| Doses | Total | ||||
|---|---|---|---|---|---|
| 0 | 1-2 | 3 | |||
| Aboriginal | Samples (n) | 257 (%)a | 77 (%) | 81 (%) | 415 (%) |
| 7vPCV serotypes | 46 (17.9) | 16 (20.8) | 8 (9.9) | 70 (16.9) | |
| Non-7vPCV serotypes | 63 (24.5) | 27 (35.1) | 38 (46.9) | 128 (30.8) | |
| Non-Aboriginal | Samples (n) | 819 (%) | 89 (%) | 102 (%) | 1010 (%) |
| 7vPCV serotypes | 110 (13.4) | 24 (27.0) | 18 (17.6) | 152 (15.0) | |
| Non-7vPCV serotypes | 72 (8.8) | 11 (12.4) | 14 (13.7) | 97 (9.6) | |
a% = proportion of samples
Note: To avoid potential bias related to health service utilization, data presented here are from children who either never received 7vPCV or received their first dose of 7vPCV before age 12 months. Among 7vPCV recipients, only samples collected >14 days after 7vPCV administration were considered post-vaccine
Some nasopharyngeal aspirates included more than one 7vPCV or non-7vPCV serotypes or both 7vPCV and non-7vPCV serotypes. Non-typeable pneumococci were excluded